Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Objective The Treatment of Early Onset Schizophrenia Spectrum Disorders Study is a publicly funded clinical trial designed to compare the therapeutic benefits, safety, and tolerability of risperidone, olanzapine, and molindone in youths with early-onset schizophrenia spectrum disorders. The rationale, design, and methods of the Treatment of Early Onset Schizophrenia Spectrum Disorders Study are described. Method Using a randomized, double-blind, parallel-group design at four sites, youths with EOSS (ages 8-19 years) were assigned to an 8-week acute trial of risperidone (0.5-6.0 mg/day), olanzapine (2.5-20 mg/day), or molindone (10-140 mg/day). Responders continued double-blind treatment for 44 weeks. The primary outcome measure was responder status at 8 weeks, defined by a 20% reduction in baseline Positive and Negative Symptom Scale scores plus ratings of significant improvement on the Clinical Global Impressions. Secondary outcome measures included assessments of psychopathology, functional impairment, quality of life, and medication safety. An intent-to-treat analytic plan was used. Results From February 2002 to May 2006, 476 youths were screened, 173 were further evaluated, and 119 were randomized. Several significant study modifications were required to address safety, the use of adjunctive medications, and the termination of the olanzapine treatment arm due to weight gain. Conclusions The Treatment of Early Onset Schizophrenia Spectrum Disorders Study will inform clinic…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical indication for antipsychotics has been also extended to conduct disorders, although with only moderate efficacy rates (31,32).”
From Pediatric psychopharmacology: Too much or too little? (2013) · cites this paper as [31]
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · cited 3×
“Responder status was defined a priori as a Clinician`s CGI-I (NIMH, 1985) score of 1 (very much improved) or 2 (much improved) plus a 20% reduction in the baseline PANSS score (Kay et al., 1987).”
MethodResultInfluentialEffectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationA Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170 · cited 1×
“The Simpson Angus Extrapyramidal Symptom Scale (Simpson and Angus, 1970), the Barnes Akathisia Scales (Barnes, 1989), and the Abnormal Involuntary Movement Scale (National Institute of Mental Health, 1985) were used to monitor EPSEs.”
MethodThe Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688 · cited 1×
“,1984), Child Behavior Checklist-Parent and Teacher versions, Youth Self-Report Form (Achenbach and Rescorla, 2001), the Quality of Life Scale (Heinrichs et al., 1984), and the Caregiver Strain Questionnaire (Brannan et al.”
Autism screening questionnaire: diagnostic validity
Berument, S. K., Rutter, M., Lord, C., Pickles, A., & Bailey, A. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.5.444 · Cited by 1,464 · cited 1×
“The Social Communication Questionnaire (Berument et al., 1999) was used to screen for pervasive developmental disorders, given the potential overlap between symptoms of pervasive developmental disorders and negative or prodromal symptoms of schizophrenia.”
MethodDiscovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.45859 · Cited by 737
Brannan, A. M., Heflinger, C. A., & Bickman, L. (1997) · Journal of Emotional and Behavioral Disorders · doi:10.1177/106342669700500404 · Cited by 452
Childhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra, S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830120020005 · Cited by 410 · cited 1×
“In two studies of treatment-refractory childhoodonset schizophrenia, clozapine was more beneficial than haloperidol for positive and negative symptoms (n = 21; Kumra et al., 1996) and superior to olanzapine for negative symptoms (n = 25; Shaw et al.”
BackgroundPractice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia
McClellan, J., & Stock, S. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.02.008 · Cited by 361
Self-citationWERRY, J. S., MCCLELLAN, J. M., & CHARD, L. (1991) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199105000-00017 · Cited by 344 · cited 1×
“Furthermore, the same psychosis module has been used to study the longitudinal course of earlyonset schizophrenia (McClellan et al., 1999; Werry et al., 1991).”
MethodSelf-citationSikich, L., Hamer, R. M., Bashford, R. A., Sheitman, B. B., & Lieberman, J. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300327 · Cited by 308 · cited 2×
“Weight gain is more often associated with atypical agents, especially olanzapine (Fleischhaker et al., 2006; Ratzoni et al., 2002; Sikich et al., 2004).”
BackgroundSelf-citationRATZONI, G., GOTHELF, D., BRAND-GOTHELF, A., REIDMAN, J., KIKINZON, L., GAL, G., PHILLIP, M., APTER, A., & WEIZMAN, R. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200203000-00014 · Cited by 237 · cited 1×
“Weight gain is more often associated with atypical agents, especially olanzapine (Fleischhaker et al., 2006; Ratzoni et al., 2002; Sikich et al., 2004).”
BackgroundChildhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison
Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., Tossell, J. W., Lenane, M., & Rapoport, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.721 · Cited by 225 · cited 2×
“, 1996) and superior to olanzapine for negative symptoms (n = 25; Shaw et al., 2006).”
BackgroundMolindone for schizophrenia and severe mental illness
Bagnall, A.-M., Fenton, M., Kleijnen, J., & Lewis, R. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002083.pub2 · Cited by 188 · cited 1×
“Molindone was chosen because of its lower propensity for weight gain (Bagnall et al., 2000).”
BackgroundEpidemiology of early-onset schizophrenia
Häfner, H., & Nowotny, B. (1995) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02190734 · Cited by 185 · cited 1×
“Youths with EOSS tend to have more severe negative symptoms, greater cognitive impairments, and higher rates of chronic functional and social impairment in comparison to individuals with adult-onset forms (Hafner and Nowotny, 1995; Rapoport and Inoff-Germain, 2000; Yang et al., 1995).”
BackgroundCorrell, C. U., Penzner, J. B., Parikh, U. H., Mughal, T., Javed, T., Carbon, M., & Malhotra, A. K. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.007 · Cited by 184 · cited 1×
“In comparison to adults, youths treated with antipsychotic agents appear to be at greater risk for metabolic problems (Correll et al., 2006) and extrapyramidal side effects (Findling et al.”
ResultRisperidone in Adolescents With Schizophrenia: An Open Pilot Study
ARMENTEROS, J. L., WHITAKER, A. H., WELIKSON, M., STEDGE, D. J., & GORMAN, J. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199705000-00021 · Cited by 150 · cited 1×
“Published reports support their benefit for this population (Armenteros et al., 1997; Findling et al., 2003; Grcevich et al., 1996; Kumra et al., 1998; Shaw et al., 2006; Simeon et al., 1995).”
BackgroundChildhood‐Onset Schizophrenia: An Open‐Label Study of Olanzapine in Adolescents
Kumra, S., Jacobsen, L. K., Lenane, M., Karp, B. I., Frazier, J. A., Smith, A. K., Bedwell, J. S., Lee, P. C., Malanga, C. J., HAMBURGER, S., et al. (1998) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199804000-00015 · Cited by 146 · cited 1×
“Published reports support their benefit for this population (Armenteros et al., 1997; Findling et al., 2003; Grcevich et al., 1996; Kumra et al., 1998; Shaw et al., 2006; Simeon et al., 1995).”
BackgroundSelf-citationPractice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia
McClellan, J., & WERRY, J. S. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107001-00002 · Cited by 141
Self-citationUse of antipsychotics in children and adolescents.
Findling, R. L., Steiner, H., & Weller, E. B. (2005) · PubMed · Cited by 135
Self-citationA controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients.
Pool, D., Bloom, W., Mielke, D. H., Jj, R., & Dm, G. (1976) · PubMed · Cited by 120
The Brief Psychiatric Rating Scale for Children.
Overall, J. E., & Pfefferbaum, B. J. (1982) · PubMed · Cited by 116
Early-Onset Psychotic Disorders: Course and Outcome Over a 2-Year Period
McClellan, J., MCCURRY, C., Snell, J. L., & DuBose, A. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199911000-00012 · Cited by 108 · cited 1×
“Furthermore, the same psychosis module has been used to study the longitudinal course of earlyonset schizophrenia (McClellan et al., 1999; Werry et al., 1991).”
MethodSelf-citationHaloperidol in schizophrenic children: early findings from a study in progress.
SPENCER, E. K., Kafantaris, V., Padron-Gayol, M., Rosenberg, C. R., & Campbell, M. (1992) · PubMed · Cited by 101
Molindone hydrochloride treatment of hospitalized children with conduct disorder.
Ll, G., Solomon, M., Pleak, R. R., & Ambrosini, P. J. (1985) · PubMed · Cited by 92
Risperidone in the Treatment of Children and Adolescents with Schizophrenia: A Retrospective Study
GRCEVICH, S. J., FINDLING, R. L., ROWANE, W. A., FRIEDMAN, L., & SCHULZ, S. C. (1996) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1996.6.251 · Cited by 92 · cited 1×
“Published reports support their benefit for this population (Armenteros et al., 1997; Findling et al., 2003; Grcevich et al., 1996; Kumra et al., 1998; Shaw et al., 2006; Simeon et al., 1995).”
BackgroundSelf-citationAntipsychotics in early onset Schizophrenia: Systematic review and meta-analysis
Armenteros, J. L., & Davies, M. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-005-0515-2 · Cited by 86
A Children's Global Assessment Scale (CGAS) (for children 4 to 16 years of age)
Shaffer, D., Gould, M. S., & Brašić, J. R. (1985) · Psychopharmacology Bulletin · Cited by 63
A Prospective, Open-Label Trial of Olanzapine in Adolescents With Schizophrenia
FINDLING, R. L., MCNAMARA, N. K., YOUNGSTROM, E. A., BRANICKY, L. A., DEMETER, C. A., & SCHULZ, S. C. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200302000-00010 · Cited by 62 · cited 1×
“Published reports support their benefit for this population (Armenteros et al., 1997; Findling et al., 2003; Grcevich et al., 1996; Kumra et al., 1998; Shaw et al., 2006; Simeon et al., 1995).”
BackgroundSelf-citationClinical Drug Monitoring in Child and Adolescent Psychiatry: Side Effects of Atypical Neuroleptics
Fleischhaker, C., Heiser, P., Hennighausen, K., Herpertz‐Dahlmann, B., Holtkamp, K., Mehler‐Wex, C., Rauh, R., Remschmidt, H., Schulz, E., & Warnke, A. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.308 · Cited by 59 · cited 1×
“Weight gain is more often associated with atypical agents, especially olanzapine (Fleischhaker et al., 2006; Ratzoni et al., 2002; Sikich et al., 2004).”
BackgroundUpdate on childhood-onset schizophrenia
Rapoport, J. L., & Inoff‐Germain, G. (2000) · Current Psychiatry Reports · doi:10.1007/s11920-000-0024-4 · Cited by 56 · cited 1×
“Youths with EOSS tend to have more severe negative symptoms, greater cognitive impairments, and higher rates of chronic functional and social impairment in comparison to individuals with adult-onset forms (Hafner and Nowotny, 1995; Rapoport and Inoff-Germain, 2000; Yang et al., 1995).”
BackgroundRisperidone Effects in Treatment-Resistant Adolescents: Preliminary Case Reports
SIMEON, J. G., CARREY, N. J., WIGGINS, D. M., MILIN, R. P., & HOSENBOCUS, S. N. (1995) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1995.5.69 · Cited by 53 · cited 1×
“Published reports support their benefit for this population (Armenteros et al., 1997; Findling et al., 2003; Grcevich et al., 1996; Kumra et al., 1998; Shaw et al., 2006; Simeon et al., 1995).”
BackgroundStudy of molindone in disturbed preschool children.
Campbell, M., Fish, B., Shapiro, T., & Floyd, A. G. (1971) · PubMed · Cited by 27
Comparison of adult manifestations of schizophrenia with onset before and after 15 years of age
Yang, P., Liu, C. ‐., Chiang, S. ‐., Chen, J. Y., & Lin, T. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09769.x · Cited by 26 · cited 1×
“Youths with EOSS tend to have more severe negative symptoms, greater cognitive impairments, and higher rates of chronic functional and social impairment in comparison to individuals with adult-onset forms (Hafner and Nowotny, 1995; Rapoport and Inoff-Germain, 2000; Yang et al., 1995).”
BackgroundMolindone for schizophrenia and severe mental illness
Bagnall, A.-M., Fenton, M., Lewis, R. A., Leitner, M., & Kleijnen, J. (2000) · doi:10.1002/14651858.cd002083 · Cited by 24
Research works printed but not linked: 3
- Kryzhanovskaya, 2006, A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia, Schizophr Res, 81, S44
- National Institute of Mental Health, 1985, Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research, Psychopharmacol Bull, 21, 765
- Simpson, 1970, A rating scale for extrapyramidal effects, Acta Psychiatr Scand, 212, 111
Cited by
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A. E., Michael, E., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050756 · Cited by 478
“Concomitant treatments with anticholinergic agents, propranolol, and benzodiazepines were guided by algorithms (28).”
InfluentialSelf-citationKumra, S., Oberstar, J. V., Sikich, L., Findling, R. L., McClellan, J. M., Vinogradov, S., & Charles Schulz, S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm109 · Cited by 186
Self-citationMcIntyre, R. S., & Jerrell, J. M. (2008) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.162.10.929 · Cited by 178
Goldstein, T. R., Fersch-Podrat, R. K., Rivera, M., Axelson, D. A., Merranko, J., Yu, H., Brent, D. A., & Birmaher, B. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0145 · Cited by 166
“Guidelines for the treatment of BP in youth identify both pharmacotherapy and psychotherapy as important components of optimal treatment (McClellan et al. 2007).”
BackgroundKryzhanovskaya, L., Schulz, S. C., Mcdougle, C., Frazier, J., Dittmann, R., Robertson-Plouch, C., Bauer, T., Xu, W., Wang, W., Carlson, J., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181900404 · Cited by 168
Self-citation
Metadata
- Authors
- McCLELLAN, J., SIKICH, L., FINDLING, R. L., FRAZIER, J. A., VITIELLO, B., HLASTALA, S. A., WILLIAMS, E., AMBLER, D., HUNT-HARRISON, T., MALONEY, A. E., RITZ, L., ANDERSON, R., HAMER, R. M., & LIEBERMAN, J. A.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- McCLELLAN, JON
- ORCID
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-08
- Volume
- 46
- Issue
- 8
- Pages
- 969-978
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W2048486175
- Cited by
- 90
- References
- 37
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 6
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institute of Mental Health (U01MH062726, K23 MH70570, U01 MH62726, U01MH061355, U01MH61355, K23MH070570, U01MH061528, U01MH061464, U01MH61528, U01MH61464)
- National Center for Research Resources (M01 RR00046, M01-RR 00037, M01RR000046, M01RR000037)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- antipsychotic drugs, risperidone, olanzapine, molindone, drug safety, suicidality, weight gain, adolescent psychiatry, treatment response, functional disability, quality of life
- MeSH terms
- Olanzapine, Adolescent, Adult, Benzodiazepines, Child, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Molindone, Schizophrenia, Time Factors, Antipsychotic Agents, Comorbidity, Age of Onset, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.